Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Open accessPublished version of a preprint
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Based on genomic analysis, 50% of high-grade serous ovarian cancers (HGSC) are predicted to have DNA repair defects. Whether this substantial subset of HGSCs actually have functional repair defects remains unknown. Here, we devise a platform for functional profiling of DNA repair in short-term patient-derived HGSC organoids. We tested 33 organoid cultures derived from 22 patients with HGSC for defects in homologous recombination (HR) and replication fork protection. Regardless of DNA repair gene mutational status, a functional defect in HR in the organoids correlated with PARP inhibitor sensitivity. A functional defect in replication fork protection correlated with carboplatin and CHK1 and ATR inhibitor sensitivity. Our results indicate that a combination of genomic analysis and functional testing of organoids allows for the identification of targetable DNA damage repair defects. Larger numbers of patient-derived organoids must be analyzed to determine whether these assays can reproducibly predict patient response in the clinic. Significance: Patient-derived ovarian tumor organoids grow rapidly and match the tumors from which they are derived, both genetically and functionally. These organoids can be used for DNA repair profiling and therapeutic sensitivity testing and provide a rapid means of assessing targetable defects in the parent tumor, offering more suitable treatment options. Cancer Discov; 8(11); 1404–21. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1333
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [125]
In the citing paper
“PDOs are a validated preclinical model to evaluate anti-cancer drug efficacy [24,25].”
From Combining Mitomycin C with inhibition of BAD phosphorylation enhances apoptotic cell death in advanced cervical cancer (2024) · cites this paper as [24]
In the citing paper
“Patient-derived organoids or tumoroids retain cellular heterogeneity and immune cells, thus are able to more strongly recapitulate a three-dimensional (3D) tumor microenvironment ex vivo compared to homogeneous cell lines (Hill et al., 2018; Kopper et al., 2019).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
In the citing paper
“Ovarian tumoroid cultures have been established from both ascitic fluid and primary tumors, to date primarily from the more common HGSOC but also from LGSOC, MOC, OCCC, and EnOC (Hill et al., 2018; De Witte et al., 2020; Nanki et al., 2020).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
In the citing paper
“In contrast, it has been noted that organoid propagation methods tend to be selective and result in a cell population that may not be representative of the original tumor heterogeneity and in turn, treatment response, particularly in patients who have undergone previous neoadjuvant therapy (Hill et al., 2018).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“Mutations were visualized with the cBioPortal OncoPrinter script (47, 48).”
MethodIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 1×
“Mutations were visualized with the cBioPortal OncoPrinter script (47, 48).”
MethodIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880 · cited 2×
“2 and Table 1), because olaparib sensitivity is a useful surrogate marker for an HR defect (7).”
BackgroundAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Self-citationOrganoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Drost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790 · cited 1×
“Large-scale studies of organoids, with comparison with patient outcomes, will be required to prove the utility of this model system in the clinic (18, 19, 21).”
ResultWhole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569 · cited 2×
“NOVEMBER 2018 CANCER DISCOVERY | 1419 Human tumors derived from several tissue types exhibit clonal heterogeneity (22, 46), and functional assays in organoids can be used to address the effects of genomic tumor heterogeneity on therapeutic response.”
BackgroundOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Cited by
Items 301–400 of 457
Kraiczy, J., & Yu, B. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.10.038 · Cited by 9
A compendium of next-generation patient-derived models for diverse cancers
ElHarouni, D., Al‐Jazrawe, M., Choi, S., Dede, M., Hinoue, T., Misek, S. A., Noh, H., Zanella, L., Tseng, Y.-Y., Francies, H. E., et al. (2026) · Nature · doi:10.1038/s41586-026-10806-y · Cited by 16
The organoid: A research model for ovarian cancer
Chang, Y., Wu, K., Harnod, T., & Ding, D. (2021) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_63_21 · Cited by 10
“The organoid model has been recently used in ovarian cancer DNA repair defect research [69].”
MethodChemoresistance in Ovarian Cancer: The Role of Malignant Ascites
Nunes, M., & Ricardo, S. A. V. (2022) · Exon Publications eBooks · doi:10.36255/exon-publications-ovarian-cancer-malignant-ascites · Cited by 14
Tsukamoto, Y., Hirashita, Y., Shibata, T., Fumoto, S., Kurogi, S., Nakada, C., Kinoshita, K., Fuchino, T., Murakami, K., Inomata, M., et al. (2023) · Cancers · doi:10.3390/cancers15164104 · Cited by 10
Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC
Littler, S., Barnes, B. M., Owen, R., Nelson, L., Tighe, A., Lin, I., Osborne, H. C., Schmidt, C. K., McGrail, J. C., & Taylor, S. S. (2025) · iScience · doi:10.1016/j.isci.2025.112555 · Cited by 9
“Despite most HGSOC suffering from replication stress 62,63 our prior study found that sensitivity to ATR, CHK1, WEE1, and PARG inhibitors was not correlated, indicating RSR-targeting drugs were not interchangeable.”
Organoids for Modeling (Colorectal) Cancer in a Dish
Rathje, F., Klingler, S., & Aberger, F. (2022) · Cancers · doi:10.3390/cancers14215416 · Cited by 10
“In addition to mammary [13] and intestinal organoids, many other types of organoids cultivated from a variety of tissues and organs were described in the past years: organoids were established for stomach [14,15], liver [16,17], pancreas [18–20], kidney [21,22], prostate [23,24], ovaries [25,26], endometrium [27], eso…”
BackgroundKast, V., & Loessner, D. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73359-9_9 · Cited by 11
Zhu, S., Gao, H., Jiang, D., Guo, G., Hou, J., Han, Y., Zhang, C., Hu, X., Indulkar, S., Kloeber, J. A., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.06.004 · Cited by 9
Venegas-Godinez, L., & Lheureux, S. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1638964 · Cited by 8
Skiba, W., Suszczyk, D., Pawłowska, A., Włodarczyk, K., Pańczyszyn, A., & Wertel, I. (2022) · Cells · doi:10.3390/cells11233851 · Cited by 9
“This model is a patient-derived 3D culture (PD3D) that faithfully recapitulates heterogeneity and the histological and genomic features of primary tumours [38,39].”
BackgroundRadomski, S. N., Dunworth, M., West, J. J., Greer, J. B., Johnston, F. M., & Ewald, A. J. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14696-6 · Cited by 8
Artificial tumor matrices and bioengineered tools for tumoroid generation
Liu, Y., Chen, P., Chang, R., Liu, X., Jhang, J.-W., Enkhbat, M., Chen, S., Wang, H., Deng, C., & Wang, P. (2024) · Biofabrication · doi:10.1088/1758-5090/ad2534 · Cited by 8
“So far, a variety of tumoroid models have been successfully established, such as breast cancer [72], bladder cancer [73], colon cancer [74, 75], gastric cancer [76], liver cancer [77], pancreatic cancer [78], ovarian cancer [79], lung cancer [80] and nasopharyngeal cancer [81].”
BackgroundLin, Y., Liu, N., Yang, C., Tan, H., Fang, C., Kang, Y., Zhao, H., Xia, N., Wang, W., Huang, X., et al. (2024) · Virology Journal · doi:10.1186/s12985-024-02502-y · Cited by 8
Self-citationEstablishing a cryopreserved biobank of living tumor tissues for drug sensitivity testing
Chen, P., Zhou, J., Chu, X., Feng, Y., Zeng, Q., Lei, J.-H., Wong, K.-P., Chan, T.-I., Lam, C.-W., Zhu, W., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.09.008 · Cited by 16
“A broad spectrum of cancer PDO models have been successfully established, allowing a better understanding of cancer development patterns and providing an ideal model for exploring how drugs interact with tumors [7 – 16].”
Liang, F., Yang, W., Zhao, H., Bakkum-Gamez, J. N., Sherman, M. E., & Kannan, N. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1979-7_30 · Cited by 7
Innate immunity mediator STING modulates nascent DNA metabolism at stalled forks in human cells
Nguyen, V. N., Brunon, S., Pavlova, M. N., Lazarchuk, P., Sharifian, R., & Sidorova, J. M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1048726 · Cited by 9
“In cancer cells these responses are often deregulated, which correlates with sensitivity to chemotherapies that interfere with DNA replication (Chaudhuri et al., 2016; Rondinelli et al., 2017; Hill et al., 2018; Cong et al., 2021).”
BackgroundCunnea, P., Fotopoulou, C., Ploski, J., Trillsch, F., Mahner, S., & Kessler, M. (2021) · Cancers · doi:10.3390/cancers13133349 · Cited by 7
“Another study comparing whole-exome sequencing (WES) data and RAD51 foci formation capacity and in vitro response to olaparib in 33 short–term organoid lines from 22 patients demonstrated that incidence of PARPi resistance is much higher than HRD signatures predict (2 out of 12 lines were sensitive to olaparib) [71].”
BackgroundBiomaterial-Based Delivery Systems for Chemotherapeutics
Gugulothu, D. B., Dhawan, D., Sachdeva, A., Deepali, & Chauhan, M. K. (2023) · Biological and medical physics, biomedical engineering · doi:10.1007/978-981-19-9786-0_4 · Cited by 10
Minoli, M., Cantore, T., Kiener, M., Fedrizzi, T., Manna, F. L., Karkampouna, S., Genitisch, V., Rodríguez, A., Klima, I., Gasperini, P., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.31.486514 · Cited by 7
Prospects and challenges of ovarian cancer organoids in chemotherapy research (Review)
Zhang, W., Ding, Y., He, H., Chen, K., Zeng, Q., Cao, X., Xiang, Y., & Zeng, H. (2025) · Oncology Letters · doi:10.3892/ol.2025.14944 · Cited by 9
“However, as evidenced by in vivo studies, HRD alone does not guarantee a response to platinum or PARPis (41), pointing to a more intricate landscape requiring further exploration.”
InfluentialSerafini, C. E., Davarzani, A., Cappabianca, D., Li, Z., Collazos, D. B., Mamaghani, D., Mao, L., Saha, K., Karumbaiah, L., & Robles, F. E. (2026) · Optica · doi:10.1364/optica.574860 · Cited by 9
Mercadante, M., Scheben, A., Estrada, J., Savas-Carstens, J., Sullivan, W., Housel, N., Sapar, M. L., Volpari, T., Hebner, J., Rusielewicz, T., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01251-7 · Cited by 7
Organoids and epithelial ovarian cancer ‑ a future tool for personalized treatment decisions?
Sisman, Y., Schnack, T. H., Høgdall, E. V. S., & Høgdall, C. K. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2462 · Cited by 7
“A total of four studies lacked statistical analyses (44,47,48,50), while three studies use one‐way ANOVA to calculate significant variation between two experimental groups (44,49,53).”
The ORFIUS complex regulates ORC2 localization at replication origins
Yang, Z., Mogre, S., He, R., Berdan, E. L., Sui, S. J. H., & Hill, S. J. (2024) · NAR Cancer · doi:10.1093/narcan/zcae003 · Cited by 6
“Cells were combed and stained as described previously ( 29 ).”
Self-citationde Kort, W. W. B., Millen, R., Driehuis, E., Devriese, L. A., van Es, R. J. J., & Willems, S. M. (2024) · Head and Neck Pathology · doi:10.1007/s12105-024-01658-x · Cited by 12
Organoids for Cancer Research: Advances and Challenges
Xin, M., Li, Q., Wang, D., & Wang, Z. (2024) · Advanced Biology · doi:10.1002/adbi.202400056 · Cited by 6
Endocrine cancer organoids in basic and translational medical research
Chen, D., Chen, Z., Yang, H., Zhang, L., Hu, C., Yang, Z., Li, P., Su, X., Liu, X., Wei, W., et al. (2025) · Science China Life Sciences · doi:10.1007/s11427-024-2888-8 · Cited by 7
“Hill et al. (2018) established a platform to analyze DNA repair function in short-term HGSOC PDOs and discovered that homologous recombination defects were positively correlated with sensitivity to PARP inhibitors and that replication fork protection defects were associated with sensitivity to…”
InfluentialCavarzerani, E., Caligiuri, I., Bartoletti, M., Corona, G., Perin, T., Palumbo, A., Ditto, A., Occhiali, T., Canzonieri, V., & Rizzolio, F. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.009 · Cited by 10
“…icle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors, while deficiencies in replication fork protection have been associated with sensitivity to carboplatin, CHK1 inhibitors, and ATR inhibitors [17].”
InfluentialPARP inhibitors in advanced prostate cancer: when to use them?
Mejia, N. M. D., García-Illescas, D., Morales‐Barrera, R., Suárez, C., Planas, J., Maldonado, X., Carles, J., & Mateo, J. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0133 · Cited by 7
SOAT1 in gallbladder cancer: Clinicopathological significance and avasimibe therapeutics
Hong, Y., Abudukeremu, X., She, F., & Chen, Y. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23733 · Cited by 6
Kordyukova, M., Bulgakov, T. K., Sorokina, M. A., Kudryashova, O. M., Abakumova, T. O., Meshcheryakova, V., Grigoriev, I. V., Senko, I. V., Shevchenko, E. K., & Belousov, V. V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052207 · Cited by 6
“Functional drug sensitivity testing (DST) using patient-derived tumor cells or tissue fragments overcomes key limitations of molecular profiling approaches by enabling identification of effective therapies even in the absence of actionable driver mutations [290,301].”
Drug screening approaches for small-molecule compounds in cancer-targeted therapy
Zhao, Y., Yuan, C., Shi, Y., Liu, X., Luo, L., Zhang, L., Pešić, M., Yao, H.-J., & Li, L. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2427185 · Cited by 6
“…inhibit the respiratory chain of hypoxic cells [110]. in another study, researchers successfully assessed the roles of eGFR and c-Met kinase inhibitors and linked prostate cancer cell phenotypic parameters to specific target activity by combining 3D cell culture techniques with image analysis [93].”
Reversing regulatory safeguards: Targeting the ATR pathway to overcome PARP inhibitor resistance
Lin, X., Qiu, Y., Soni, A., Stuschke, M., & Iliakis, G. E. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.200934 · Cited by 10
Guo, L., Xia, Z., Wang, J., Xiao-ling, Y., Wu, C., Luo, Q., & Zhao, C. (2025) · View · doi:10.1002/viw.20240127 · Cited by 5
Using organoid models to predict chemotherapy efficacy: the future of precision oncology?
Forsythe, S. D., Pu, T., & Skardal, A. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1685868 · Cited by 6
“Hill et al. (2018) continued to analyze DNA repair deficiencies on treatment efficacy on a collection of 33 different Matrigel-supported organoid cultures derived from 23 patients with ovarian tumors [98].”
BackgroundInfluentialvan Biljon, L., Fashemi, B., Rodriguez, J., Graham, O., Compadre, A. J., Fuh, K. C., Khabele, D., & Mullen, M. (2023) · Journal of Visualized Experiments · doi:10.3791/64881 · Cited by 7
Trillsch, F., Reichenbach, J., Czogalla, B., Kraus, F. B. T., Burges, A., Mahner, S., & Kessler, M. (2024) · Journal of Visualized Experiments · doi:10.3791/66467 · Cited by 7
Quercetin Promote the Chemosensitivity in Organoids Derived from Patients with Breast Cancer
Meng, S., Cao, Y., Lu, L., Li, X., Sun, S., Jiang, F., Lu, J., Fan, D., Han, X., & Yao, T. (2024) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s494901 · Cited by 9
Kim, K., Kim, S. H., Lee, J., Kim, Y., Lee, S., & Park, E. (2023) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2023.34.e45 · Cited by 5
“Regarding RAD51 measurement methods, IHC is a convenient and cost-effective tool that is desirable for clinical diagnostic practice; however, only a few studies have reported RAD51 IHC evaluation in HGSC [18-20].”
BackgroundMethodResultInfluentialThe Multiple Faces of the MRN Complex: Roles in Medulloblastoma and Beyond
Petroni, M., Monica, V. L., Fabretti, F., Augusto, M., Battaglini, D., Polonara, F., Giulio, S. D., & Giannini, G. (2023) · Cancers · doi:10.3390/cancers15143599 · Cited by 5
Cao, L.-L., Sun, S., Yang, F., Wang, H., Liu, X., Ge, N., Guo, J., Wang, S., & Song, X. (2019) · Endoscopic Ultrasound · doi:10.4103/eus.eus_13_19 · Cited by 5
“This affects the results of drug sensitivity tests, leading to limited clinical value and applications.[9] Patient-derived tumor xenografts, to a certain extent, can simulate cancer conditions in vivo, but the disadvantages such as low transplantation success rate, long culture period, and high cost limit their applic…”
BackgroundCX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
Xuan, J., Pearson, R. B., & Sanij, E. (2020) · Molecular & Cellular Oncology · doi:10.1080/23723556.2020.1805256 · Cited by 5
“Recent studies in patient-derived HGSOC organoids identified fork stability, measured following treatment with replication stalling agents, as a biomarker of response to chemotherapy and inhibitors of ATR and CHK1 (checkpoint kinase 1).(8) In Hill et al, seventeen of twenty eight (61%) of HGSOC organoids had unstable…”
BackgroundHR eye & MMR eye: one-day assessment of DNA repair-defective tumors eligible for targeted therapy
Saito, S., Kato, S., Arai, U., En, A., Tsunezumi, J., Mizushima, T., Tateishi, K., & Adachi, N. (2025) · Nature Communications · doi:10.1038/s41467-025-59462-2 · Cited by 4
“Several approaches have been reported to functionally measure HR capacity without constructing a stable clone harboring recombination substrates, for example, using a Rad51 foci formation assay 54,55 ,areplicationfork/DNA fi berassay 56 ,orqPCRanalysisofgene-targeting frequency 57 .”
Dahl, M. J., Lofgren, K. A., Haugen, C., Harmon, G. E., Hughes, S. P., & Dahl, K. D. C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1368592 · Cited by 4
Applications and perspectives of tumor organoids in radiobiology (Review)
Jin, Y., Wang, K., Tang, Y., & Zheng, D. (2024) · Oncology Reports · doi:10.3892/or.2024.8759 · Cited by 5
“Hill et al (89) indicated that the platelet‑derived growth factor receptor‑ β /vascular endothelial growth factor‑2/STAT2 signaling pathway induces radiotherapy resistance in ovarian cancer organoids by influ‑ encing the oxygen‑dependent glycolysis pathway.”
BackgroundSwain, B., & Maddi, S. (2024) · Nature Cell and Science · doi:10.61474/ncs.2024.00008 · Cited by 6
Thorel, L., Elie, N., Morice, P., Weiswald, L., Florent, R., Perréard, M., Giffard, F., Ricou, A., Leman, R., Babin, G., et al. (2025) · Laboratory Investigation · doi:10.1016/j.labinv.2025.104097 · Cited by 4
Current Status and Perspectives of Patient-Derived Models for Ewing’s Sarcoma
Kondo, T. (2020) · Cancers · doi:10.3390/cancers12092520 · Cited by 5
“Recent studies indicated that short-term cultured cells present with features that are more similar to those of original tumors than long-term cultured cells, and thus are more useful for drug screening in both two- and three-dimensional culture conditions [37,44].”
BackgroundShah, M. A. F., Din, S. U., & Shah, A. A. (2021) · International Conference on Innovative Computing (ICIC) · doi:10.1109/icic53490.2021.9692921 · Cited by 4
Perréard, M., Florent, R., Thorel, L., Vincent, A., Weiswald, L., & Poulain, L. (2022) · médecine/sciences · doi:10.1051/medsci/2022149 · Cited by 8
Advanced strategies in organoid/organ-on-a-chip for female reproductive diseases
Zhou, Y., Chen, M., Wang, F., Xu, C., Wen, Y., He, Z., & Zhu, Y. (2025) · Biofabrication · doi:10.1088/1758-5090/ae2b10 · Cited by 3
“These organoids exhibited hallmark HGSC morphological features, including nuclear pleomorphism and epithelial disarray [131], though their proliferative capacity was limited.”
Skin Organoid Research Progress and Potential Applications
Li, H., Ren, K., Wang, C., & Bu, W.-B. (2021) · International Journal of Dermatology and Venereology · doi:10.1097/jd9.0000000000000201 · Cited by 5
Models of fibrolamellar carcinomas, tools for evaluation of a new era of treatments
Song, J., Lu, M., He, Z., & Zhang, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1459942 · Cited by 4
Duan, Y., Jin, Y., Jia, Y., Zhao, M., Bai, L., Zhu, S., Wei, Z., Zhang, S., Yang, B., & Li, Y. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123723 · Cited by 5
Rankin, E. B. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000490 · Cited by 3
“foci assembly following irradiation, correlates with response to poly ADP ribose polymerase inhibition.(30) These studies highlight the”
BackgroundHart, P. C., Bajwa, P., & Kenny, H. A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73359-9_5 · Cited by 3
Development of Homologous Recombination Functional Assays for Targeting the DDR
Oswald, A. J., & Gourley, C. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_4 · Cited by 2
Patient-derived organoids as a model to study tubo-ovarian carcinoma: a pathologist’s perspective
Alves‐Vale, C., Galvão, B., Silvestre, A. R., Pereira, J. S., Bei, L., Fernandes, J. P., Borralho, P., Carmo‐Fonseca, M., & Custódio, N. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01766-4 · Cited by 2
“2) [23].”
InfluentialCalanca, N., Rainho, C. A., Maeda, D. K., Côrtes, L., Villacis, R. A. R., Bizinelli, D., Kuasne, H., Aagaard, M. M., Fokdal, L. U., Steffensen, K. D., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118668 · Cited by 2
Lynce, F. C., Graham, N., Kochupurakkal, B. S., Nguyen, H. Q., Bychkovsky, B., Poorvu, P. D., Attaya, V., Davis, R., DiLullo, M. K., D’Andrea, A. D., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0571 · Cited by 3
Self-citationChen, Y., Xu, N. L. J., Dong, M., Liu, W., Liu, Z., Sun, G., & Jia, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773734 · Cited by 2
Lynch, K. N., Liu, J. F., Kesten, N., Chow, K.-H., Shetty, A., He, R., Afreen, M. F., Yuan, L., Matulonis, U. A., Growdon, W. B., et al. (2021) · Cancers · doi:10.3390/cancers13092195 · Cited by 2
“If the cell can protect the forks, the ratio will be near one [28].”
BackgroundSelf-citationFOXM1 Promotes Non-Small Cell Lung Cancer Progression by Increasing CHEK1 Expression
Lu, X., Chen, J., Han, G., Ding, C., Li, C., Xu, C., Cui, Y., Ju, S., Tong, X., & Zhao, J. (2025) · Current Medical Science · doi:10.1007/s11596-025-00055-x · Cited by 2
Gynecological malignancy organoids: A game changer for personalized medicine
Ding, Z., Chang, X., Qu, X., Hua, K., & Qiu, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189405 · Cited by 3
Functional ex vivo DNA fibre assay to measure replication dynamics in breast cancer tissue
Chen, M., van den Tempel, N., Bhattacharya, A., Yu, S., Rutgers, B., Fehrmann, R. S. N., de Haas, S., van der Vegt, B., & van Vugt, M. A. T. M. (2024) · The Journal of Pathology · doi:10.1002/path.6328 · Cited by 2
“…fresh tumour samples has, to our knowledge, not been reported elsewhere, a functional replication fork protection assay was previously performed on High Grade Serous Ovarian Cancer (HGSOC) organoids and showed an association with sensitivity to carboplatin, CHK1, and ATR inhibitor treatment [31].”
Yamanoi, K., & Mandai, M. (2021) · Current human cell research and applications · doi:10.1007/978-981-33-6013-6_7 · Cited by 2
Biomarkers of Homologous Recombination Deficiency in the era of PARP inhibitors
Piombino, C., & Cortesi, L. (2022) · Annals of Research in Oncology · doi:10.48286/aro.2022.48 · Cited by 2
Clinical significance of RAD51C and its contribution to ovarian carcinogenesis.
Lü, X., Liu, S., Xiong, Z., Wang, F., Li, X.-Y., & Deng, H. (2020) · Europe PMC (PubMed Central) · Cited by 2
Going beyond genomics in precision oncology
Paassen, I., & Rubin, M. A. (2026) · Nature Medicine · doi:10.1038/s41591-025-04153-0 · Cited by 2
Ghanem, Y. K., Odwan, H., Yang, M., Malone, V., Alenazi, F., Saadeh, F. A., Gray, S., Doherty, D. G., Martin, C., O'Toole, S. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.28.702206 · Cited by 2
Zhou, C., Wang, J., Zhang, Y., Zhou, Z., Wu, C., Wang, L., & Guo, L. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00833f · Cited by 1
Ye, M., Wu, Y., Chen, Z., Zhai, Q., Li, L., Yan, Z., Li, M., Gu, C., Wen, Y., Liao, S., et al. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101411 · Cited by 4
He, Z.-B., & Duan, X. (2026) · Animals and zoonoses. · doi:10.1016/j.azn.2026.06.007 · Cited by 1
Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial
Sellars, M., Frank, J. A., Shim, B., Vanasse, A. P., Liu, R., Forman, C., Tu, C. R., Tabata, K. K., Kowelewski, A., Cheng, S.-C., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04717-8 · Cited by 1
Self-citationKonecny, G. E., Chander, C., & Zhang, L. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000564 · Cited by 1
Construction of Multicellular Tumor-on-a-Chip Models for Ovarian Cancer Research
Ye, J., Lin, H., Zhang, Z., Xu, S., Yang, F. L., ZhuanSun, X.-M., Ji, F., Zhang, Y. F., Zhu, Y., Zhang, J., et al. (2025) · Engineering · doi:10.1016/j.eng.2025.08.028 · Cited by 2
Establishment of Patient-Derived Organoids for Pediatric Cancer Research
Younis, M., Arjmandi, T., Haque, M., McClain, K., Angelo, T. W., Back, F., Gandra, D., Moore, A., Behura, C. G., Spiegelman, V. S., et al. (2026) · Cancers · doi:10.3390/cancers18091465 · Cited by 1
“Moreover, the relative ease of genetically modifying them to express fluorescent reporters of specific tumoral sub-populations [34,35] should help to dissect and monitor, over time and by 3D imaging [36], the mechanisms identified as playing a causal role in tumor escape.”
Solarczyk, K. J., & Kordon-Kiszala, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1118716 · Cited by 2
“Within the ever-growing list of known DDR players RAD51, 53BP1, pRPA and pKAP1 gained the most interest in recent years (Fernandez-Capetillo et al., 2002; Mochan et al., 2004; Zellweger et al., 2015; Hill et al., 2018).”
BackgroundSrivastava, A., Unterweger, C., Guttmann, S., Wolf, A., Müllauer, L., Schepelmann, M., Castillo‐Tong, D. C., & Bartl, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188866 · Cited by 1
“This is evidenced by HGSOC organoids re-establishing CA125 secretion and papillary structures that mirror the histology of primary tumors [24].”
Chudakova, D. A., Skorova, E., & Reshetov, I. V. (2020) · Biotekhnologiya · doi:10.21519/0234-2758-2020-36-3-3-15 · Cited by 1
Yang, Q. (2022) · eLife · doi:10.7554/elife.83867.sa0 · Cited by 1
Pooladanda, V., Xu, R. F., Zarrella, D. T., Matoba, Y., Shimada, C., Kumar, S., Kim, E., DiBenedetto, P. J., Qin, X., Sarosiek, K. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.20.699925 · Cited by 1
In the literature: December 2018
Gambardella, V., Fleitas, T., & Cervantes, A. M. R. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000468
“In an elegant study, performed by a group of investigators belonging to different centres from the University of Harvard in Boston and the University of Washington at Seattle, short-term organoid cultures were generated from 22 patients with high-grade serous ovarian cancer.(6) The authors hypothesised that patient-de…”
Search for drug discovery targets focusing on cancer stroma
Kamada, H. (2019) · Translational and Regulatory Sciences · doi:10.33611/trs.1_58
“Ovary Surgery High-grade serous ovarian cancers 100 CRB, Olaparib, Prexasertib, VE-822, DOX, Taxol, GEM [50]”
BackgroundPromising agents on the horizon
Soragni, A., & Trivedi, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819840-7.00003-0
Models of ovarian cancer to test new agents
Sodi, V. L., Craig, A. D., Peri, S., & Connolly, D. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819840-7.00012-1
Organoid As a Novel Technology for Disease Modeling
Sever, T., CEVIK, I., Calibasi‐Kocal, G., Ellidokuz, E., & Başbınar, Y. (2021) · Journal of Basic and Clinical Health Sciences · doi:10.30621/jbachs.868837
“…Kidney Hwang et al., 2019(56); Wang et al., 2017(57); Batchelder et al., 2015(58) Ovary Nanki et al., 2020(59); Kopper et al., 2019(60); Hill et al., 2018(19) Lung Shi et al., 2020(61); Kim et al., 2019(62); Dijkstra et al., 2018(63) Liver Broutier et al., 2017(64) Brain Bhaduri et…”
Leveraging technological opportunities in cancer genomics
Valle-Inclán, J. E. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/480
Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids
Volpari, T., Hebner, J., Aiyar, R. S., & Martin, L. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00080-3
Moyano‐Galceran, L. (2021) · Figshare
The Organoids: Derivations and Applications
Faried, A., Hermanto, Y., Amalia, P. R., & Bolly, H. M. B. (2022) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-030-93056-1_1
Therapy for Recurrent High-Grade Epithelial Ovarian Cancer—The Current Status and Future Trends
Harindran, V. D., Sadanandan, V. P. S., Sreedath, P. V., Prashanth, P., Sajeevan, K. V., Sreedharan, P. S., & Warrier, N. E. (2022) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0042-1742321
“11”
Molecular Biology, Genetics, and Translational Models of Human Cancer
Traub, B., Scheufele, F., Viswanathan, S. R., Meyerson, M. M., & Tuveson, D. A. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm003.pub2
Färkkilä, A., Rodríguez, A., Oikkonen, J., Gulhan, D., Nguyen, H. Q., Domínguez-Soberanes, J., Ramos, S., Mills, C. E., Pérez‐Villatoro, F., Lazaro, J., et al. (2023) · doi:10.1158/0008-5472.c.6512719.v1
Self-citationHong, D. S., Moore, K. N., Bendell, J. C., Karp, D. D., Wang, J. S.-Z., Ulahannan, S. V., Jones, S. F., Wu, W., Donoho, G. P., Ding, Y., et al. (2023) · doi:10.1158/1078-0432.c.6530435
Hong, D. S., Moore, K. N., Bendell, J. C., Karp, D. D., Wang, J. S.-Z., Ulahannan, S. V., Jones, S. F., Wu, W., Donoho, G. P., Ding, Y., et al. (2023) · doi:10.1158/1078-0432.c.6530435.v1
Engineering Approaches in Ovarian Cancer Cell Culture
Iwanicki, M., Pavlovič, T., & Behboodi, P. (2023) · Current cancer research · doi:10.1007/978-3-031-22802-5_8
Author response: High-grade serous ovarian carcinoma organoids as models of chromosomal instability
Vias, M., Gavarró, L. M., Sauer, C. M., Sanders, D. A., Piskorz, A., Couturier, D., Ballereau, S. J., Hernando, B., Schneider, M. P., Hall, J. A. M., et al. (2023) · eLife · doi:10.7554/elife.83867.sa2
Metadata
- Authors
- Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., Yang, C., Morizane, R., Kochupurakkal, B. S., Do, K. T., Konstantinopoulos, P. A., Liu, J. F., Bonventre, J. V., Matulonis, U. A., Shapiro, G. I., Berkowitz, R. S., Crum, C. P., & D'Andrea, A. D.
- Affiliations
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Washington (US)
- Dana-Farber Cancer Institute (US)
- 1Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
- ORCID
- Hill, Sarah J.
- Decker, Brennan
- Roberts, Emma A.
- Horowitz, Neil S.
- Worley, Michael J.
- Feltmate, Colleen M.
- Nucci, Marisa R.
- Swisher, Elizabeth M.
- Nguyen, Huy
- Yang, Chunyu
- Morizane, Ryuji
- Kochupurakkal, Bose S.
- Do, Khanh T.
- Konstantinopoulos, Panagiotis A.
- Liu, Joyce F.
- Bonventre, Joseph V.
- Matulonis, Ursula A.
- Shapiro, Geoffrey I.
- Berkowitz, Ross S.
- Crum, Christopher P.
- Venue
- Cancer Discovery
- Published
- 2018-11-01
- Volume
- 8
- Issue
- 11
- Pages
- 1404-1421
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6365285
- OpenAlex
- W2891058330
- Cited by
- 452
- References
- 49
- Citations by year
- 2026: 37 · 2025: 43 · 2024: 67 · 2023: 78 · 2022: 66 · 2021: 72 · 2020: 63 · 2019: 25 · 2018: 1
- FWCI
- 15.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Stand Up to Cancer (SU2C) (SU2C-AACR-DT16-15)
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) (R37HL052725, P01HL048546)
- U.S. Department of Defense (DOD) (BC151331P1)
- Leukemia and Lymphoma Society (LLS) (6237-13)
- Breast Cancer Research Foundation (BCRF)
- Richard and Susan Smith Family Foundation
- The Bridge Project
- HHS | NIH | National Cancer Institute (NCI) (UM1 CA186709)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- high-grade serous ovarian cancer, DNA repair deficiency, patient-derived tumor organoids, homologous recombination deficiency, replication fork protection, PARP inhibitor sensitivity, carboplatin sensitivity, CHK1 inhibitor, ATR inhibitors, predictive biomarkers, targeted therapy
- MeSH terms
- Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, DNA Repair, DNA Replication, Female, Follow-Up Studies, Humans, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Organ Culture Techniques, Organoids, Ovarian Neoplasms, Prognosis, Pyrazines, Pyrazoles, Biomarkers, Tumor, Carboplatin, Cystadenocarcinoma, Serous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.